Magruder, Linda Ray

Amy Wigmore is a partner and a vice chair of the firm's Litigation/Controversy Department, and a member of the Intellectual Property Litigation Practice Group. She joined the firm in 1998. Ms. Wigmore focuses on patent litigation and complex commercial litigation and has represented clients in state and federal courts in several jurisdictions.

Practice

Ms. Wigmore has extensive experience representing clients in the biotechnology industry. She has counseled clients and litigated cases concerning technology license disputes. Ms. Wigmore also has represented pharmaceutical and telecommunications companies in patent infringement suits.

In addition, Ms. Wigmore has represented clients in cases involving the misappropriation of trade secrets, unfair competition, breach of contract, employment disputes, civil rights claims and test security issues. She also has handled congressional investigations and internal corporate investigations.

Ms. Wigmore has significant experience in all facets of the litigation process, including drafting and arguing dispositive motions, managing complex document production efforts, taking and defending depositions, working with experts and examining witnesses at trial. She also has represented clients in alternative dispute resolution proceedings.

Recent Highlights

• Represents a patentee and its exclusive licensee in a patent infringement action in which the validity of the patent at issue was affirmed after a three-week jury trial.
• Represents a pharmaceutical company in multiple patent cases and commercial arbitrations involving biotechnology patents.
• Represents a pharmaceutical company in a Hatch Waxman patent infringement case involving a treatment for HIV.
• Served as lead counsel for the defendant in a patent infringement case concerning digital audio technology.
• Represented a medical device company in patent litigation concerning safety needles and blood collection devices.
• Represented a pharmaceutical company in a license dispute concerning drug-eluting stents.
• Successfully obtained a stay of a patent infringement action against a pharmaceutical company pending reexamination of the asserted patent.
• Represented a pharmaceutical company in a Hatch Waxman patent infringement case involving a treatment for Parkinson's disease.
• Represented a biotechnology company in a highly successful five-year legal battle involving a licensing dispute with a major clinical diagnostics company. The 10-week jury trial and subsequent appeal led to a $1.4 billion acquisition of our client by the defendant.